Not available
Quote | InflaRx N.V. (NASDAQ:IFRX)
Last: | $1.63 |
---|---|
Change Percent: | 0.0% |
Open: | $1.74 |
Close: | $1.63 |
High: | $1.74 |
Low: | $1.61 |
Volume: | 47,378 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | InflaRx N.V. (NASDAQ:IFRX)
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
Message Board Posts | InflaRx N.V. (NASDAQ:IFRX)
Subject | By | Source | When |
---|---|---|---|
Closing of offering, here comes first stop $6.25 | Gator44 | investorshub | 04/18/2023 2:25:38 PM |
$IFRX should go slowly 5$ + | frans | investorshub | 04/17/2023 6:53:22 PM |
$IFRX 4.2 now slowly on the move | frans | investorshub | 04/17/2023 4:47:27 PM |
in here at 4.10 | frans | investorshub | 04/17/2023 4:30:35 PM |
Still in downtrend and they will keep diluting | the_stockoracle | investorshub | 04/13/2023 4:10:45 PM |
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...